Skip to main content
Advertisement
Advertisement

UNCY

UNCY logo

Unicycive Therapeutics, Inc. Common Stock

4.81
USD
Sponsored
-0.15
-3.02%
Sep 23, 16:00 UTC -4
Closed
exchange

After-Market

4.82

+0.01
+0.10%

UNCY Earnings Reports

Positive Surprise Ratio

UNCY beat 8 of 21 last estimates.

38%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.32
Implied change from Q2 26 (Revenue/ EPS)
--
/
+433.33%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-3.03%

Unicycive Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 12, 2026, UNCY reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.34 USD, resulting in a 82.51% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.80% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.32 USD, with revenue projected to reach -- USD, implying an increase of 433.33% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Unicycive Therapeutics, Inc. Common Stock reported EPS of -$0.06, beating estimates by 82.51%, and revenue of $0.00, 0% as expectations.
The stock price moved up 7.8%, changed from $5.00 before the earnings release to $5.39 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 8 analysts, Unicycive Therapeutics, Inc. Common Stock is expected to report EPS of -$0.32 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement